Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
Zezhong Liu, Wei Xu, Shuai Xia, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 190

Showing 51-75 of 190 citing articles:

Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2
Jingbo Huang, Weiqi Wang, Hailun Li, et al.
Antiviral Research (2024) Vol. 227, pp. 105905-105905
Closed Access | Times Cited: 3
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses
Ryo Shinnakasu, Shuhei Sakakibara, Hiromi Yamamoto, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 12
Open Access | Times Cited: 26
Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations
Konlavat Siriwattananon, Suwimon Manopwisedjaroen, Balamurugan Shanmugaraj, et al.
Vaccines (2021) Vol. 9, Iss. 7, pp. 744-744
Open Access | Times Cited: 24
RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
Xiaoyan Pan, Jian Shi, Xue Hu, et al.
Cell Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 23
Paxlovid accelerates cartilage degeneration and senescence through activating endoplasmic reticulum stress and interfering redox homeostasis
Keyu Kong, Yongyun Chang, Hua Qiao, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 17
RETRACTED: Safety and immunogenicity of a recombinant receptor‐binding domain‐based protein subunit vaccine (Noora vaccine™) against COVID‐19 in adults: A randomized, double‐blind, placebo‐controlled, Phase 1 trial
Jafar Salimian, Ali Ahmadi, Jafar Amani, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 2
Open Access | Times Cited: 16
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
Xinling Wang, Lujia Sun, Zezhong Liu, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 9
Interaction of serum proteins with SARS-CoV-2 RBD
Yue‐wen Yin, Yan-Jing Sheng, Min Wang, et al.
Nanoscale (2021) Vol. 13, Iss. 30, pp. 12865-12873
Closed Access | Times Cited: 22
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
Darielys Santana-Mederos, Rocmira Pérez-Nicado, Yanet Climent-Ruíz, et al.
RSC Chemical Biology (2021) Vol. 3, Iss. 2, pp. 242-249
Open Access | Times Cited: 22
Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections
Balamurugan Shanmugaraj, Konlavat Siriwattananon, Ashwini Malla, et al.
Pathogens (2021) Vol. 10, Iss. 8, pp. 1051-1051
Open Access | Times Cited: 21
Dental Healthcare Amid the COVID-19 Pandemic
Rabia Tariq Butt, Omer Sefvan Janjua, Sana Mehmood Qureshi, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 21, pp. 11008-11008
Open Access | Times Cited: 21
A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice
Laura Lazo, Mónica Béquet‐Romero, Gilda Lemos, et al.
Vaccine (2022) Vol. 40, Iss. 8, pp. 1162-1169
Open Access | Times Cited: 15
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection
Natasha M. Clark, Sanath Kumar Janaka, William R. Hartman, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0257930-e0257930
Open Access | Times Cited: 15
Protein Scaffold‐Based Multimerization of Soluble ACE2 Efficiently Blocks SARS‐CoV‐2 Infection In Vitro and In Vivo
Alişan Kayabölen, Uğur Akcan, Doğancan Özturan, et al.
Advanced Science (2022) Vol. 9, Iss. 27
Open Access | Times Cited: 15
Animal models for SARS-CoV-2 and SARS-CoV-1 pathogenesis, transmission and therapeutic evaluation
Udhaya Bharathy Saravanan, Mayurikaa Namachivayam, Rajesh Jeewon, et al.
World Journal of Virology (2022) Vol. 11, Iss. 1, pp. 40-56
Open Access | Times Cited: 14
Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor
Najing Cao, Yanxing Cai, Xin Huang, et al.
mBio (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 2
Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine
Navid Dashti, Forough Golsaz‐Shirazi, Haleh Soltanghoraee, et al.
European Journal of Microbiology and Immunology (2024) Vol. 14, Iss. 3, pp. 228-242
Open Access | Times Cited: 2
Rationally designed multimeric nanovaccines using icosahedral DNA origami for display of SARS-CoV-2 receptor binding domain
Qingqing Feng, Keman Cheng, Lizhuo Zhang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2
I. V. Krasilnikov, Aleksandr V. Kudriavtsev, Anna Vakhrusheva, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 69-69
Open Access | Times Cited: 12
Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies
Faezeh Maghsood, Mohammad Mehdi Amiri, Amir‐Hassan Zarnani, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 12
A comprehensive overview on the transmission, pathogenesis, diagnosis, treatment, and prevention of SARS‐CoV‐2
Yiting Zhang, Setrice Patricia Clarke, Huanwu Wu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 5
Closed Access | Times Cited: 7
A Newly Identified Spike Protein Targeted Linear B‐Cell Epitope Based Dissolvable Microneedle Array Successfully Eliciting Neutralizing Activities against SARS‐CoV‐2 Wild‐Type Strain in Mice
Lin Li, Zhongpeng Zhao, Xiaolan Yang, et al.
Advanced Science (2023) Vol. 10, Iss. 20
Open Access | Times Cited: 7
Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate
Alexandra Moros, Antoni Prenafeta, Antonio Barreiro, et al.
Vaccine (2023) Vol. 41, Iss. 35, pp. 5072-5078
Open Access | Times Cited: 7
Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2
Yisheng Sun, Jing-Jing Zhou, Han-Ping Zhu, et al.
Viruses (2021) Vol. 13, Iss. 10, pp. 1936-1936
Open Access | Times Cited: 17
Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening
John S. Schardt, Ghasidit Pornnoppadol, Alec A. Desai, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 16

Scroll to top